The agenda for the 3 June 2015 TC meeting is now available. The Commission will consider the following technologies:

• Etanercept (Enbrel) - new indication
• Tenofovir disoproxil fumarate with emtricitabine and elvitegravir and cobicistat (Stribild) - review of SMR
• Emtricitabine with rilpivirine hydrochloride and tenofovir disoproxil fumarate (Eviplera) - new indication
• Mercaptamine bitartrate (Procysbi) - new medicine
• Cholic acid (Kolbam) - new medicine
• Ranibizumab (Lucentis) - new indication (resubmission)

For more details, go to: http://www.has-sante.fr/portail/upload/docs/application/pdf/2015-05/odj_ct_03062015_internet.pdf [French]